Luye Pharma of Yantai has been approved to start Japan trials of its novel treatment for depression, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) in extended release tablet form. Ansofaxine Hydrochloride ER Tablets (LY03005) has already begun Phase III trials for LY03005 in China and the US. Luye expects LY03005 will avoid the side-effects of serotonin-only treatments for depression. The candidate is part of Luye’s larger effort to expand its portfolio of central nervous system drugs.
Source: China Biotoday